Once-weekly 1.6mg/m2 bortezomib BCD regimen in elderly patients with newly diagnosed multiple myeloma who are ineligible for high-dose therapy

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-15006337

Enrollment

Unknown

Registered

2015-05-02

Start date

2010-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

elderly patients with newly diagnosed multiple myeloma who are ineligible for high-dose therapy:Once-weekly 1.6mg/m2 bortezomib BCD regimen

Eligibility

Sex/Gender

All

Age

65 Years to 81 Years

Inclusion criteria

Inclusion criteria: elderly patients with newly diagnosed, symptomatic multiple myeloma and measurable disease who had not received prior therapy. 1. Age >=65 years and unsuitable for HDT with ASCT; 2. Eastern Cooperative Oncology Group performance status of 1000/uL, hemoglobin level >10g/dL and platelets >80000/uL.

Exclusion criteria

Exclusion criteria: 1. Significant pre-existing peripheral neuropathy (defined as >=grade 3); 2. Left ventricular ejection fraction <=0.50, or those who had symptoms of congestive heart failure; 3. Uncontrolled angina, or significant arrhythmias; 4. Recurrent deep vein thrombosis or pulmonary thromboembolism; 5. Chemotherapeutic drug allergy, for example, patients with hypersensitivity to bortezomib.

Design outcomes

Primary

Measure	Time frame
response rate;	—

Secondary

Measure	Time frame
overall surviva;progression-free survival;	—

Countries

China

Contacts

Public ContactZhu Qi

zhuqi70@hotmail.com+86 13764188348

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026